NewAmsterdam Pharma achieved a significant regulatory milestone with EMA acceptance of Marketing Authorization Applications for obicetrapib in Europe, while share count increased 4.7% and cash burned down significantly.
The EMA's acceptance of MAAs in August 2025 represents meaningful progress toward commercialization in Europe through the Menarini partnership, potentially validating the company's clinical development strategy. However, the company's cash position declined substantially by $281.7M year-over-year, raising questions about funding runway as they advance toward commercialization.
The company shows classic biotech cash burn patterns with revenue declining 50.6% to $22.5M while SG&A expenses surged 51% to $106.4M, likely reflecting increased commercial preparation activities. Cash and equivalents fell significantly from $771.7M to $490.0M, though this remains a substantial war chest, while the overall balance sheet contracted 11% but maintained a strong net cash position with liabilities decreasing 19.9%. The financial profile suggests heavy investment in advancing toward commercialization while maintaining adequate liquidity.
SG&A up 51% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Revenue declined 50.6% — significant demand weakness or market share loss warrants investigation.
Cash declined 36.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Current assets declined 21.7% — monitor working capital adequacy and short-term liquidity.
Liabilities reduced 19.9% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
Net income grew 15.6% — bottom-line growth signals improving overall business health.
Total assets contracted 11% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →